Pregnancy Point of Care Testing Market Size
Global Pregnancy Point of Care Testing Market reached US$ 2.68 billion in 2025 and is expected to reach US$ 4.35 billion by 2033, growing at a CAGR of 6.4% during the forecast period 2026-2033.
Pregnancy point-of-care testing (POCT) is a form of testing in which the analysis is performed where healthcare is provided close to or near the patient. Pregnancy Point-of-care testing is preferably pregnancy testing kits, fertility testing kits, and others.
Pregnancy Point of Care Testing Market Scope
| Metrics | Details |
| CAGR | 6.4% |
| Size Available for Years | 2023-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | By Product Type, By Test Type, By Distribution Channel, By Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Drug Class Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For More Insights about the Market Request Free Sample
Pregnancy Point of Care Testing Market Trends
The growing cases of gynecological disorders, fertility issues, and preference for fast and accurate point-of-care tests are driving the growth of global pregnancy point-of-care testing in the forecast period.
The Growing Cases of Gynecological Disorders, Infertility and Increased Adoption of Point-of-Care Testing are Driving the Global Market Growth in the Forecast Period.
A gynecological disorder is a condition that affects the normal function of female reproductive organs, including the breasts and organs in the abdominal and pelvic area, namely the womb (uterus), ovaries, fallopian tubes, vagina and vulva., Such as Cervical Dysplasia, Pelvic Floor Prolapse, Polycystic Ovarian Syndrome, and Uterine Fibroids.
The growing cases of the mentioned and other gynecological disorders are boosting the growth of the global pregnancy point-of-care testing market in the forecast period. For instance, according to the Hopkins Medicine Organization, Cervical dysplasia affects between 250,000 and one million women throughout the United States every year. Though women of any age can develop cervical dysplasia, the condition occurs most frequently in those between ages 25 and 35.
Furthermore, the increased adoption of point-of-care testing methods owing to their benefits also contributes to market growth. For example, point-of-care testing (POCT) allows immediate clinical decision-making in the diagnosis process (rule-in or rule-out), treatment choice and monitoring, and prognosis. Thus, growing cases of gynecological disorders, infertility and increased adoption of point-of-care testing are driving the global market growth in the forecast period.
The Frequent Pregnancy POC Testing Errors will Restrain the Growth of the Global Pregnancy Point-of-Care Testing Market.
However, errors may be more frequent with pregnancy POC testing than with laboratory testing, which can occur because the POC testing environment is generally less controlled than laboratory conditions, and the results can be at higher risk of external interference than laboratory processes, which can lead to inaccuracy. Thus, the frequency of errors will hamper the global pregnancy point-of-care testing market.
Key Developments
- March 2026: QuidelOrtho announced an updated digital pregnancy‑test platform featuring enhanced smartphone‑linked readouts and improved hCG‑detection thresholds, positioning the system for broader use in primary‑care and community‑health settings. The iteration embeds algorithm‑driven calibration routines to reduce false‑negative calls and integrates with a cloud‑based clinician dashboard for longitudinal patient tracking.
- January 2026: Swiss‑based Roche Diagnostics unveiled a new multiplexed point‑of‑care cartridge that combines early pregnancy confirmation with markers for key complications (such as ectopic‑risk indicators), expanding the utility beyond standalone hCG‑based tests in ambulatory‑care environments. This platform leverages microfluidic assay‑on‑chip technology and aims to bridge the gap between rapid strips and centralized lab‑based analyzers.
Pregnancy Point of Care Testing Market Segment Analysis
The HCG Urine Pregnancy Testing Kits are Expected to Dominate the Market
The hCG urine pregnancy testing kits are expected to dominate the global market owing to the ease of availability, low cost and accuracy. The hCG urine pregnancy testing kits contain special strips that detect HCG. Most hCG Urine pregnancy testing kits are 99% efficacious when utilized accurately, which is about the same precision rate as pregnancy tests carried out in a healthcare provider's office.
These test kits are available in the majority of drug or grocery shops. They're easy to use and inexpensive, for example, Mylab's PregaScreen is Priced at INR 55 only. Reading the instructions on these tests is essential before taking the test.
For most of these test kits, HCG can be identified in urine till ten days post conception. Nevertheless, taking it after missing a period lowers the possibility of obtaining a false-negative result. A missed period generally occurs about 14 days after conception.
The product has a single-step pregnancy test device that does not need the collection of urine in a dropper or a container, making it the easiest and most convenient method to test pregnancy at home. Thus, from the data mentioned above, it is estimated that the hCG Urine pregnancy testing kits will dominate the global pregnancy point-of-care testing market in the forecast period.
Pregnancy Point of Care Testing Market Geographical Share
The North American Region Holds the Largest Global Pregnancy Point-of-Care Testing Market Share.
The CDC declares that in heterosexual women 15 to 49 years who have never given childbirth, approximately 19% experience infertility. A woman is less probable to encounter infertility if she has had at least one birth. Roughly 6% of these married women 15 to 49 years have infertility. Over the past few years, there has been an advancement in the incidence of unplanned pregnancies, dramatically leading to high demand for pregnancy test kits and devices across North America.
As published in the National Library of Medicine, an estimated 3 million unwanted pregnancies and 1.5 induced abortions are happening in the United States. In addition, growing awareness levels on the usage of pregnancy self-detection devices increased awareness of the benefits and advantages obtained by using these pregnancy detection kits, the rising rate of teenage pregnancy, the rise in government support for the use of pregnancy tests and a high rise in need for self-test pregnancy kits are further boosting the pregnancy testing market growth in North America.
In addition, the advancement in technological advancements in pregnancy test kits owing to the ongoing movement in launching new products in the market integrated with other market developments such as acquisition, mergers, expansion and others in this region ensure its dominance over the global market. Therefore, the growing number of infertility cases, increasing incidences of unplanned pregnancies and growing awareness are estimated to contribute to the dominance of North America over the global market in the forecast period.
Pregnancy Point of Care Testing Companies and Competitive Landscape
The pregnancy point-of-care testing market is moderately competitive due to the presence of key local and global players. Some key players are Abbott Laboratories, EKF Diagnostics Holdings plc, BioMérieux SA, Mylab, Atlas Medical, Quidel Corporation, BIOSYNEX SA, Prestige Brands Holdings, Swiss Precision Diagnostics (SPD) GmbH, Piramal Enterprises, NG BIOTECH SAS among others.
Abbott Laboratories
Overview:
Abbott Laboratories was established in 1888 and is headquartered in Chicago, Illinois, United States. Abbott Laboratories is one of the leading healthcare companies worldwide that delivers a wide range of medical devices, diagnostics, branded generic medicines and nutritional products.
Product Portfolio:
Abbott Laboratories’ pregnancy point-of-care testing product portfolio has ALERE hCG Easy Pregnancy Test: The Alere hCG Easy Pregnancy Test is a rapid diagnostic device for qualitatively detecting human Chorionic Gonadotrophin (hCG) in urine.
The Global Pregnancy Point-of-Care Testing Market Report Would Provide Access to Approximately 40+ Market Data Tables, 45+ Figures and a Range of 200 (approximate) Pages.
